Related Experiment Video

Updated: Jan 30, 2026

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia
08:31

Murine Model of Leukemia Relapse to Induction Chemotherapy for Acute Lymphoblastic Leukemia

Published on: October 17, 2025

683

[Roles of CCAAT enhancer binding protein α in acute myeloblastic leukemia]

Ting Shi1, Xiujin Ye1

  • 1Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou 310003, China.

Zhejiang Da Xue Xue Bao. Yi Xue Ban = Journal of Zhejiang University. Medical Sciences
|January 30, 2019
PubMed

Insights

CCAAT enhancer binding protein α (C/EBPα) gene dysregulation drives acute myeloid leukemia (AML) by altering p42 and p30 protein levels. Restoring the C/EBPα expression ratio is a potential therapeutic strategy for AML.

Area of Science:

  • Molecular Biology
  • Hematology
  • Oncology

Background:

  • CCAAT enhancer binding protein α (C/EBPα) is crucial for myeloid hematopoiesis.
  • Aberrant C/EBPα gene expression is a key mechanism in acute myeloid leukemia (AML) pathogenesis.
  • Specific C/EBPα isoforms, p42 and p30, are implicated in AML development.

Purpose of the Study:

  • To review the current research on the role of C/EBPα in AML pathogenesis.
  • To elucidate the mechanisms by which C/EBPα dysregulation contributes to AML.
  • To inform medical decision-making for AML treatment strategies targeting C/EBPα.

Main Methods:

  • Literature review of studies on C/EBPα and AML.
  • Analysis of gene expression patterns and protein isoform ratios in AML.
  • Investigation of the functional consequences of C/EBPα alterations in myeloid development.

Main Results:

  • Uncontrolled C/EBPα gene expression leads to p30 over-expression and p42 loss.
  • These changes in C/EBPα isoforms are associated with AML occurrence.
  • Restoring the p42/p30 expression ratio may counteract AML development.

Conclusions:

  • C/EBPα plays a critical role in the pathogenesis of AML.
  • Targeting C/EBPα expression, specifically p42 restoration or p30 pathway inhibition, offers potential therapeutic avenues for AML.
  • Further research into C/EBPα regulation is vital for advancing AML treatment.

More Related Videos

Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells09:16

Investigation of the Transcriptional Role of a RUNX1 Intronic Silencer by CRISPR/Cas9 Ribonucleoprotein in Acute Myeloid Leukemia Cells

Published on: September 1, 2019

8.0K
In Ovo Xenografting of Patient-Derived Acute Lymphoblastic Leukemia (ALL) Cells (PDX-ALL)06:48

In Ovo Xenografting of Patient-Derived Acute Lymphoblastic Leukemia (ALL) Cells (PDX-ALL)

Published on: August 1, 2025

512

Related Concept Videos

Role of Proteins in the Human Body01:28

Role of Proteins in the Human Body

Proteins are the building block of life. They are also  the most abundant macromolecules with as many diverse roles in the body. They are part of many structural components that provide unique shapes and structures to animal cells, tissues, and organs. In addition, they also act as biological catalysts and carry out several anabolic and catabolic reactions. Notably, some proteins are chemical messengers and regulate many critical processes, such as metabolism, growth, and development. They...
6.4K
Factors Affecting Protein-Drug Binding: Protein-Related Factors01:20

Factors Affecting Protein-Drug Binding: Protein-Related Factors

Drug binding to proteins is a key aspect of pharmacokinetics and can influence a drug's distribution, absorption, and elimination in the body. Several factors, including the drug's physiochemical properties, protein concentration, disease states, and the number of binding sites on the protein, influence this process.
The physicochemical properties of a drug play a significant role in its ability to bind to proteins. Lipophilic drugs, which dissolve in fats, oils, and lipids, can be...
554
Protein and Protein Structure02:15

Protein and Protein Structure

Proteins are one of the most abundant organic molecules in living systems and have the most diverse range of functions of all macromolecules. Proteins may be structural, regulatory, contractile, or protective. They may serve in transport, storage, or membranes; or they may be toxins or enzymes. Their structures, like their functions, vary greatly. They are all, however, amino acid polymers arranged in a linear sequence.
A protein's shape is critical to its function. For example, an enzyme...
87.4K
The Equilibrium Binding Constant and Binding Strength02:18

The Equilibrium Binding Constant and Binding Strength

The equilibrium binding constant (Kb) quantifies the strength of a protein-ligand interaction. Kb can be calculated as follows when the reaction is at equilibrium:
15.0K
Drug Distribution: Plasma Protein Binding01:29

Drug Distribution: Plasma Protein Binding

Drugs predominantly attach to plasma proteins, with only a small percentage remaining unbound. The unbound portion can be calculated as one minus the bound fraction. Acidic drugs form large, inactive complexes by reversibly binding to plasma albumin, which prevents them from diffusing across biological barriers. These drug-protein complexes act as reservoirs for the drugs. As the concentration of unbound drugs decreases, these complexes quickly dissociate to release the free drug, maintaining...
8.8K
Protein-Drug Binding: Determination Methods01:22

Protein-Drug Binding: Determination Methods

Determining protein-drug binding can be achieved through indirect and direct methods, each providing valuable insights into the interaction between proteins and drugs.
Indirect methods involve isolating the bound drug from its free form in biological samples such as blood, serum, or plasma. These techniques aim to measure the percentage of drugs bound to proteins. Equilibrium dialysis is a commonly used method where the free drug concentration at equilibrium is measured by separating the bound...
648